Although one of the published studies has reported that the shRNAs decreased the expression of α-synuclein and attenuated dopamine neuron degeneration in rat PD model induced with 1-methyl-4-phenyl 1,2,3,6-tetrahydropyridine (MPTP) (Liu et al., 2014; Zhang et al., 2016), however, other techniques, such as decreasing inflammation via class II transactivator or caspase-1 inhibition by shRNA, have also been tried instead of directly targeting SNCA (Li et al., 2020). Here, SNCA is linked to Parkinson disease.